C12N 2770/24123
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2770/24123 (Virus like particles [vlp]) appears on 50 US grants and 92 published applications in this corpus.
Search patents in C12N- Granted patents
- 50
- Published applications
- 92
- Assignees
- 58
- Inventors
- 164
- Latest grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 0 | 4 |
| 2009 | 2 | 2 |
| 2010 | 0 | 1 |
| 2011 | 2 | 1 |
| 2012 | 2 | 2 |
| 2013 | 0 | 1 |
| 2014 | 1 | 2 |
| 2015 | 4 | 3 |
| 2016 | 0 | 4 |
| 2017 | 3 | 5 |
| 2018 | 4 | 12 |
| 2019 | 5 | 8 |
| 2020 | 4 | 13 |
| 2021 | 11 | 3 |
| 2022 | 5 | 6 |
| 2023 | 2 | 8 |
| 2024 | 2 | 6 |
| 2025 | 2 | 6 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development14 Apr 2026US 12,600,752 B2The University of North Carolina at Chapel Hill
- Multivalent virus like particle vaccines23 Dec 2025US 12,502,425 B2Texas Tech University System
- Nanostructured lipid carriers and stable emulsions and uses thereof21 Jan 2025US 12,201,722 B2Access To Advanced Health Institute
- Mature virus-like particles of flaviviruses24 Sep 2024US 12,098,165 B2Chiang Mai University
- Recombinant measles virus expressing zika virus prM and E proteins2 Jan 2024US 11,857,616 B2Centre National De La Recherche Scientifique
- Dengue vaccine3 Sep 2026US 2026/0256903 A1VLP Therapeutics, LLC
- Multivalent display on enveloped particles with human oligomerization domains18 Sep 2025US 2025/0288662 A1Achelois Biopharma, Inc.
- Nanostructured lipid carriers and stable emulsions and uses thereof31 Jul 2025US 2025/0241854 A1Access To Advanced Health Institute
- Compositions comprising modified flavivirus e glycoproteins and methods of making and using the same12 Jun 2025US 2025/0188130 A1The University of North Carolina at Chapel Hill
- Nucleic acid compositions for delivering exogenous polynucleotides and methods of use29 May 2025US 2025/0171802 A1Vyro Bio Inc.
Most cited
By later US patents
- High potency immunogenic zika virus compositions92US 10,273,269 B2ModernaTX, Inc. · 2019
- Zika RNA vaccines85US 10,449,244 B2ModernaTX, Inc. · 2019
- Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein50US 8,715,694 B2Altravax, Inc. · 2014
- Nanostructured lipid carriers and stable emulsions and uses thereof20US 11,141,377 B2Infectious Disease Research Institute · 2021
- Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use12US 9,000,141 B2The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · 2015